focus -WSS

focus

author：focus 2025-09-30 11:06:29 - browse：755

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： How to save health care price transparency rules

WSS

Creating egg and sperm cells from stem cells raises ethical issues

Asbestos, a deadly carcinogen, banned by EPA

Future doctors should be trained to promote social change

RaDonda Vaught links Vanderbilt hospital issues to patient death

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Colonoscopy prep: Liquid

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pushing for an NIH office for post

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Male and female sex labels in research insufficient, scientists say

At least 13 dead in Texas as scorching temps continue

John Green on his newest strategy for fighting tuberculosis

Dobbs anniversary: the lost opportunity of abortion as health care

EPA limits use of carcinogenic gas for sterilizing medical devices

United colonoscopy coverage change 'may cost lives,' doctors say

Asbestos, a deadly carcinogen, banned by EPA

focus

Nurses recount patients attacks

Medicare coverage of Wegovy, once blocked, now looks possible

Readout Newsletter: CAR

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Why depression after traumatic brain injury is distinct

John Green on his newest strategy for fighting tuberculosis

knowledge

focus

explore

hotspot